Synergy Pharmaceuticals (NASDAQ: SGYP) is one of 293 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Synergy Pharmaceuticals to similar businesses based on the strength of its dividends, risk, valuation, institutional ownership, profitability, analyst recommendations and earnings.

Analyst Ratings

This is a breakdown of current ratings for Synergy Pharmaceuticals and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Synergy Pharmaceuticals 1 0 9 0 2.80
Synergy Pharmaceuticals Competitors 758 3015 11129 227 2.72

Synergy Pharmaceuticals currently has a consensus price target of $8.90, suggesting a potential upside of 216.73%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 33.70%. Given Synergy Pharmaceuticals’ stronger consensus rating and higher possible upside, research analysts plainly believe Synergy Pharmaceuticals is more favorable than its peers.

Valuation and Earnings

This table compares Synergy Pharmaceuticals and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Synergy Pharmaceuticals $2.41 million -$216.83 million -2.42
Synergy Pharmaceuticals Competitors $260.16 million $66.28 million -6.83

Synergy Pharmaceuticals’ peers have higher revenue and earnings than Synergy Pharmaceuticals. Synergy Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Institutional & Insider Ownership

71.5% of Synergy Pharmaceuticals shares are owned by institutional investors. Comparatively, 51.0% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 3.8% of Synergy Pharmaceuticals shares are owned by insiders. Comparatively, 16.9% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility & Risk

Synergy Pharmaceuticals has a beta of 1064.55, suggesting that its stock price is 106,355% more volatile than the S&P 500. Comparatively, Synergy Pharmaceuticals’ peers have a beta of 6.66, suggesting that their average stock price is 566% more volatile than the S&P 500.


This table compares Synergy Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Synergy Pharmaceuticals N/A -485.02% -202.73%
Synergy Pharmaceuticals Competitors -5,535.02% -456.00% -42.64%

Synergy Pharmaceuticals Company Profile

Synergy Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders. TRULANCE is designed to replicate the function of uroguanylin. Dolcanatide is being evaluated for inflammatory bowel disease (IBD). TRULANCE is approved in the United States under the trademark name TRULANCE, for the treatment of adults with chronic idiopathic constipation (CIC). In addition, it is developing TRULANCE for the treatment of adults with irritable bowel syndrome with constipation (IBS-C). Dolcanatide is designed to be an analog of uroguanylin with enhanced resistance to standard digestive breakdown by proteases in the intestine.

Receive News & Stock Ratings for Synergy Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.